This single-center, retrospective study investigated the predictive value of PD-L1 positivity scored by CPS when compared with TPS in 187 patients with metastatic NSCLC treated with monotherapy immune checkpoint–based immunotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.